Molecular targets for disrupting leukocyte trafficking during multiple sclerosis
暂无分享,去创建一个
[1] Sarah Morrow,et al. The safety and efficacy of IFN-β products for the treatment of multiple sclerosis , 2007 .
[2] M. Calabrese,et al. The safety profile of cyclophosphamide in multiple sclerosis therapy , 2007, Expert opinion on drug safety.
[3] A. Akbar,et al. The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery , 2007, Nature Reviews Immunology.
[4] J. Greenwood,et al. Statins and the vascular endothelial inflammatory response. , 2007, Trends in immunology.
[5] K. Asadullah,et al. Targeting leukocyte trafficking to inflamed skin – still an attractive therapeutic approach? , 2007, Experimental dermatology.
[6] Shailendra Giri,et al. GSNO attenuates EAE disease by S‐nitrosylation‐mediated modulation of endothelial‐monocyte interactions , 2007, Glia.
[7] S. Morrow,et al. The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. , 2007, Expert opinion on drug safety.
[8] B. T. Hawkins,et al. Increased blood–brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases , 2006, Diabetologia.
[9] R. Klein,et al. CXCL12 Limits Inflammation by Localizing Mononuclear Infiltrates to the Perivascular Space during Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.
[10] C. Dijkstra,et al. Diapedesis of monocytes is associated with MMP‐ mediated occludin disappearance in brain endothelial cells , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] M. Filippi,et al. Blockade of chemokine signaling in patients with multiple sclerosis , 2006, Neurology.
[12] M. Filippi,et al. Glatiramer acetate therapy for multiple sclerosis: a review , 2006, Expert opinion on drug metabolism & toxicology.
[13] Michael J. Ramsbottom,et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients , 2006, Journal of Neuroimmunology.
[14] P. Musiani,et al. Triggering CD40 on endothelial cells contributes to tumor growth , 2006, The Journal of experimental medicine.
[15] R. Gold,et al. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. , 2006, Brain : a journal of neurology.
[16] Ludwig Kappos,et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[17] S. Youssef,et al. Statins in the treatment of central nervous system autoimmune disease , 2006, Journal of Neuroimmunology.
[18] Shailendra Giri,et al. 5‐aminoimidazole‐4‐carboxamide‐1‐beta‐4‐ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial–monocyte interaction , 2006, Journal of neuroscience research.
[19] Alexander V. Favorov,et al. Three allele combinations associated with Multiple Sclerosis , 2006, BMC Medical Genetics.
[20] Rhonda R. Voskuhl,et al. Treatment with an Estrogen Receptor α Ligand Is Neuroprotective in Experimental Autoimmune Encephalomyelitis , 2006, The Journal of Neuroscience.
[21] E. Granieri,et al. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis , 2006, Multiple sclerosis.
[22] K. Murphy,et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.
[23] J. Caillé,et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. , 2006, AJNR. American journal of neuroradiology.
[24] Lawrence Steinman,et al. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation , 2006, Nature Reviews Immunology.
[25] C. Brosnan,et al. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[26] G. Opdenakker,et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis , 2006, The Journal of experimental medicine.
[27] Severe Disease, Unaltered Leukocyte Migration, and Reduced IFN-γ Production in CXCR3−/− Mice with Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.
[28] Younghun Jung,et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. , 2006, Bone.
[29] E. Frohman,et al. Multiple sclerosis--the plaque and its pathogenesis. , 2006, The New England journal of medicine.
[30] A. Siva. The spectrum of multiple sclerosis and treatment decisions , 2006, Clinical Neurology and Neurosurgery.
[31] G. Comi,et al. Intensive immunosuppression in multiple sclerosis , 2006, Neurological Sciences.
[32] E. Ponomarev,et al. CD40 Expression by Microglial Cells Is Required for Their Completion of a Two-Step Activation Process during Central Nervous System Autoimmune Inflammation1 , 2006, The Journal of Immunology.
[33] R. Lechler,et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis , 2006, Journal of Neuroimmunology.
[34] N. Peng,et al. Lovastatin reduces apoptosis and downregulates the CD40 expression induced by TNF-alpha in cerebral vascular endothelial cells. , 2006, Current neurovascular research.
[35] N. Rothwell,et al. The role of inflammation in CNS injury and disease , 2006, British journal of pharmacology.
[36] R. Ransohoff,et al. The expression and function of chemokines involved in CNS inflammation. , 2006, Trends in pharmacological sciences.
[37] Matthias Mack,et al. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. , 2006, Brain : a journal of neurology.
[38] B. Engelhardt. Molecular mechanisms involved in T cell migration across the blood–brain barrier , 2006, Journal of Neural Transmission.
[39] B. Weinshenker,et al. CCR5Δ32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis , 2005, Journal of Neuroimmunology.
[40] A. Satoskar,et al. Cutting Edge: Macrophage Migration Inhibitory Factor Is Necessary for Progression of Experimental Autoimmune Encephalomyelitis1 , 2005, The Journal of Immunology.
[41] R. D. Hatton,et al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.
[42] P. Scherle,et al. Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344 , 2005, The Journal of Immunology.
[43] S. Barnum,et al. PSGL-1 is not required for development of experimental autoimmune encephalomyelitis , 2005, Journal of Neuroimmunology.
[44] L. Fugger,et al. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? , 2005, Brain : a journal of neurology.
[45] M. Panzara,et al. Natalizumab and progressive multifocal leukoencephalopathy. , 2005, The New England journal of medicine.
[46] B. Engelhardt,et al. P-Selectin Glycoprotein Ligand 1 Is Not Required for the Development of Experimental Autoimmune Encephalomyelitis in SJL and C57BL/6 Mice1 , 2005, The Journal of Immunology.
[47] E. Goetzl,et al. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network , 2005, Nature Reviews Immunology.
[48] H. Hartung,et al. Putative mechanisms of action of statins in multiple sclerosis – comparison to interferon-β and glatiramer acetate , 2005, Journal of the Neurological Sciences.
[49] L. Boon,et al. Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE , 2005, Journal of Neuroimmunology.
[50] C. Whitacre,et al. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. , 2005, The journal of peptide research : official journal of the American Peptide Society.
[51] C. Polman,et al. Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of Interferon beta-1b in patients with Secondary Progressive Multiple Sclerosis , 2005, Journal of Neurology.
[52] L. Piccio,et al. Efficient Recruitment of Lymphocytes in Inflamed Brain Venules Requires Expression of Cutaneous Lymphocyte Antigen and Fucosyltransferase-VII1 , 2005, The Journal of Immunology.
[53] E. Waubant,et al. An open label study of the effects of rituximab in neuromyelitis optica , 2005, Neurology.
[54] A. Vandenbark. TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. , 2005, Current drug targets. Inflammation and allergy.
[55] Andrew M Blamire,et al. MRI Reveals That Early Changes in Cerebral Blood Volume Precede Blood–Brain Barrier Breakdown and Overt Pathology in MS-like Lesions in Rat Brain , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[56] T. Mcclanahan,et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.
[57] H. Hartung,et al. Evaluation of HMG-CoA Reductase Inhibitors for Multiple Sclerosis , 2005, CNS drugs.
[58] B. Weinshenker,et al. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. , 2005, Journal of neuroimmunology.
[59] J. Dwyer,et al. Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis , 2004, Journal of neuroscience research.
[60] J. Russell,et al. TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation , 2004, Journal of Neuroimmunology.
[61] M. Nedergaard,et al. The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.
[62] I. Elovaara,et al. Increase in CCR5 Δ32/Δ32 genotype in multiple sclerosis , 2004 .
[63] Jacqueline Quandt,et al. The Beta Chemokines CCL4 and CCL5 Enhance Adhesion of Specific CD4+ T Cell Subsets to Human Brain Endothelial Cells , 2004, Journal of neuropathology and experimental neurology.
[64] R. Tuma,et al. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model , 2004, Multiple sclerosis.
[65] K. Dorovini‐Zis,et al. Induction of β-chemokine secretion by human brain microvessel endothelial cells via CD40/CD40L interactions , 2004, Journal of Neuroimmunology.
[66] Shailendra Giri,et al. Potential Targets of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor for Multiple Sclerosis Therapy , 2004, The Journal of Immunology.
[67] T. Lehtimäki,et al. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. , 2004, Acta neurologica Scandinavica.
[68] D. Comings,et al. Association of CCR5 delta32 deletion with early death in multiple sclerosis. , 2004, Genetics in medicine : official journal of the American College of Medical Genetics.
[69] Frauke Zipp,et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. , 2004, Brain : a journal of neurology.
[70] H. Lassmann,et al. CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis , 2003, Journal of Neuroimmunology.
[71] Alireza Minagar,et al. Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.
[72] I. Humphreys,et al. A Critical Role for OX40 in T Cell–mediated Immunopathology during Lung Viral Infection , 2003, The Journal of experimental medicine.
[73] C. Teuscher,et al. The Protective Effect of 17 (cid:1) -Estradiol on Experimental Autoimmune Encephalomyelitis Is Mediated through Estrogen Receptor- (cid:2) , 2003 .
[74] F. Sellebjerg,et al. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system , 2003, Brain Research Bulletin.
[75] P. Adamson,et al. Lovastatin inhibits brain endothelial cell Rho‐mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[76] G. Bernardi,et al. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS , 2003, Journal of leukocyte biology.
[77] S. Miller,et al. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212 , 2003 .
[78] M. Trojano,et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes , 2003, Journal of Neuroimmunology.
[79] R. Kastelein,et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain , 2003, Nature.
[80] M. Denkinger,et al. In Vivo Blockade of Macrophage Migration Inhibitory Factor Ameliorates Acute Experimental Autoimmune Encephalomyelitis by Impairing the Homing of Encephalitogenic T Cells to the Central Nervous System , 2003, The Journal of Immunology.
[81] P. Bongrand,et al. Effect of Atorvastatin on Adhesive Phenotype of Human Endothelial Cells Activated By Tumor Necrosis Factor Alpha , 2003, Journal of cardiovascular pharmacology.
[82] A. Vandenbark,et al. Oral Feeding with Ethinyl Estradiol Suppresses and Treats Experimental Autoimmune Encephalomyelitis in SJL Mice and Inhibits the Recruitment of Inflammatory Cells into the Central Nervous System 1 , 2003, The Journal of Immunology.
[83] K. Dorovini‐Zis,et al. CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium , 2003, Journal of Neuroimmunology.
[84] G. Kollias,et al. Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[85] David H. Miller,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.
[86] J. Dwyer,et al. 17Beta-estradiol treatment profoundly down-regulates gene expression in spinal cord tissue in mice protected from experimental autoimmune encephalomyelitis. , 2003, Archivum immunologiae et therapiae experimentalis.
[87] C. Teuscher,et al. The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. , 2003, The American journal of pathology.
[88] S. Miller,et al. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. , 2003, The Journal of clinical investigation.
[89] K. Kalunian,et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.
[90] F. Mach. Toward a role for statins in immunomodulation. , 2002, Molecular interventions.
[91] S. Youssef,et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease , 2002, Nature.
[92] E. Lo,et al. Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. , 2002, Journal of neurotrauma.
[93] P. Kubes,et al. Overlapping Roles of P-Selectin and α4 Integrin to Recruit Leukocytes to the Central Nervous System in Experimental Autoimmune Encephalomyelitis1 , 2002, The Journal of Immunology.
[94] C. Culmsee,et al. A Dual Role for the SDF-1/CXCR4 Chemokine Receptor System in Adult Brain: Isoform-Selective Regulation of SDF-1 Expression Modulates CXCR4-Dependent Neuronal Plasticity and Cerebral Leukocyte Recruitment after Focal Ischemia , 2002, The Journal of Neuroscience.
[95] A. Wierinckx,et al. Interferon-β directly influences monocyte infiltration into the central nervous system , 2002, Journal of Neuroimmunology.
[96] F. Dumont. IDEC-131. IDEC/Eisai. , 2002, Current opinion in investigational drugs.
[97] E. Butcher,et al. Chemokines in rapid leukocyte adhesion triggering and migration. , 2002, Seminars in immunology.
[98] J. Antel,et al. Migration of multiple sclerosis lymphocytes through brain endothelium. , 2002, Archives of neurology.
[99] Eugene C. Butcher,et al. Molecular Mechanisms Involved in Lymphocyte Recruitment in Inflamed Brain Microvessels: Critical Roles for P-Selectin Glycoprotein Ligand-1 and Heterotrimeric Gi-Linked Receptors1 , 2002, The Journal of Immunology.
[100] Lieping Chen,et al. Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis1 , 2002, The Journal of Immunology.
[101] B. Engelhardt,et al. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. , 2002, The Journal of clinical investigation.
[102] S. Ostrovidov,et al. Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis. , 2002, The Journal of clinical investigation.
[103] M. Sharief. Heightened intrathecal release of soluble CD137 in patients with multiple sclerosis , 2002, European journal of neurology.
[104] H. D. de Vries,et al. Interferon-beta directly influences monocyte infiltration into the central nervous system. , 2002, Journal of neuroimmunology.
[105] J. Antel,et al. Regulation of Th1 and Th2 Lymphocyte Migration by Human Adult Brain Endothelial Cells , 2001, Journal of neuropathology and experimental neurology.
[106] F. Sellebjerg,et al. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS , 2001, Neurology.
[107] J. Goverman,et al. A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis , 2001, The Journal of experimental medicine.
[108] B. Becher,et al. The Clinical Course of Experimental Autoimmune Encephalomyelitis and Inflammation Is Controlled by the Expression of Cd40 within the Central Nervous System , 2001, The Journal of experimental medicine.
[109] A. Juedes,et al. Resident and Infiltrating Central Nervous System APCs Regulate the Emergence and Resolution of Experimental Autoimmune Encephalomyelitis1 , 2001, The Journal of Immunology.
[110] B. Rollins,et al. Absence of Monocyte Chemoattractant Protein 1 in Mice Leads to Decreased Local Macrophage Recruitment and Antigen-Specific T Helper Cell Type 1 Immune Response in Experimental Autoimmune Encephalomyelitis , 2001, The Journal of experimental medicine.
[111] Y. Itoyama,et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling , 2001, Journal of Neuroimmunology.
[112] S. Miller,et al. Autoimmune Intervention by CD154 Blockade Prevents T Cell Retention and Effector Function in the Target Organ1 , 2001, The Journal of Immunology.
[113] Kenji Hayashida,et al. Stromal Cell-Derived Factor-1-CXC Chemokine Receptor 4 Interactions Play a Central Role in CD4+ T Cell Accumulation in Rheumatoid Arthritis Synovium1 , 2000, The Journal of Immunology.
[114] D. Mukhopadhyay,et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. , 2000, Blood.
[115] H. Weiner,et al. Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the Cc Chemokine Receptor (Ccr2) , 2000, The Journal of experimental medicine.
[116] A. Evans,et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.
[117] K. Frei,et al. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. , 2000, Brain : a journal of neurology.
[118] W. Kuziel,et al. Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis , 2000, The Journal of experimental medicine.
[119] H. Weiner,et al. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent , 2000, European journal of immunology.
[120] W. Kuziel,et al. Induction of experimental autoimmune encephalomyelitis in C57BL / 6 mice deficient in either the chemokine macrophage inflammatory protein‐1α or its CCR5 receptor , 2000, European journal of immunology.
[121] G. Davies-Jones,et al. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. , 2000, Brain : a journal of neurology.
[122] K. Hirata,et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. , 2000, Biochemical and biophysical research communications.
[123] B. Engelhardt,et al. Interaction of α4-integrin with VCAM-1 is involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro , 2000, Journal of Neuroimmunology.
[124] B. Engelhardt,et al. Role of glucocorticoids on T cell recruitment across the blood-brain barrier , 2000, Zeitschrift für Rheumatologie.
[125] X. Montalban,et al. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. , 1999, Brain : a journal of neurology.
[126] R. Kikinis,et al. Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis , 1999, Neurology.
[127] Jacqueline Palace,et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS , 1999, Neurology.
[128] D. MacManus,et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. , 1999, Neurology.
[129] I. Weissman,et al. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[130] Jakob S. Jensen,et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.
[131] M. Pasparakis,et al. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein‐induced experimental autoimmune encephalomyelitis , 1999, European journal of immunology.
[132] K. Frei,et al. Severity of symptoms and demyelination in MOG‐induced EAE depends on TNFR1 , 1999, European journal of immunology.
[133] S. Miller,et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. , 1999, The Journal of clinical investigation.
[134] A. Strosberg,et al. ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells. , 1998, Journal of immunology.
[135] M. Trojano,et al. Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system , 1998, Multiple sclerosis.
[136] H. Hartung,et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. , 1998, Brain : a journal of neurology.
[137] B. Engelhardt,et al. E- and P-selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. , 1997, Blood.
[138] G. Stewart,et al. The CCR5 deletion mutation fails to protect against multiple sclerosis. , 1997, Human immunology.
[139] Haidi zhang,et al. CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation , 1997, Journal of Molecular Medicine.
[140] J. Cossins,et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor , 1997, Journal of Neuroimmunology.
[141] W. Hickey,et al. PECAM‐1 (CD31) expression in the central nervous system and its role in experimental allergic encephalomyelitis in the rat , 1996, Journal of neuroscience research.
[142] L. Picker,et al. Lymphocyte Homing and Homeostasis , 1996, Science.
[143] Hans Lassmann,et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions , 1995, Annals of neurology.
[144] S. Karlik,et al. A monoclonal antibody to α4‐integrin reverses the MR‐detectable signs of experimental allergic encephalomyelitis in the Guinea pig , 1995 .
[145] C. Raine,et al. The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.
[146] A. Broocks,et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients a with multinle sclerosis , 1994, Neurology.
[147] H. Weiner,et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. , 1994, Science.
[148] M. G. Oliver,et al. Cloning, sequence comparison and in vivo expression of the gene encoding rat P-selectin. , 1994, Gene.
[149] T. Springer. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.
[150] A. Beaudet,et al. Molecular cloning and analysis of in vivo expression of murine P-selectin. , 1992, Blood.
[151] R. Hughes. Pathogenesis of multiple sclerosis. , 1992, Journal of the Royal Society of Medicine.
[152] F. Sánchez‐Madrid,et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.
[153] O Henriksen,et al. Quantitation of blood‐brain barrier defect by magnetic resonance imaging and gadolinium‐DTPA in patients with multiple sclerosis and brain tumors , 1990, Magnetic resonance in medicine.
[154] B. Uitdehaag,et al. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages , 1990, The Journal of experimental medicine.
[155] J. Mussini,et al. [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.